Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Nursing Home & Skilled Nursing Facility Experts

Analysis of: Antisoma's ASA404 1800 mg/m2 lung cancer trial will report positive survival data (www.therapeuticsdaily.com)
ASA404 is a small-molecule vascular disrupting agent that selectively disrupts established tumour blood vessels, in theory allowing chemotherapy to reach tumor cells. The data to date in NSCLC is quite promising, with significant increases in overall and medial survival when combined with...
Analysis of: Philips SpeechMagic Used In Largest Deployment Of Front-End Radiology Speech Recognition In The UK (www.medicalnewstoday.com)
In the modern era of medicine, where documentation and communication is important, fast turn around of dictated reports (radiology, consultation, progress notes) is important for an efficient workflow. Speech recognition software has improved dramatically over the last decade, allowing for relatively...
Analysis of: Blue Shield of California to pay $31M in quality bonuses to state medical groups (www.fiercehealthcare.com)
Pay for performance is here, and being used in actual reimbursements.    This is an example of this in the private payor model.
Analysis of: Poniard Pharmaceuticals Announces Initiation of Picoplatin Phase 2 Trial in First-line Treatment of Hormone-Refractory Prostate Cancer in Combination with Docetaxel and Prednisone (money.cnn.com)
Taxotere with prednisone is the standard first line chemotherapy for hormone refractory prostate cancer based on the results of the TAX 327 trial.   The ongoing phase II trial looks to see if the addition of a platinum based agent to taxotere improves outcomes in hormone refractory prostate...
August 20, 2007
A long way to go
Analysis of: Phase I intravenous trial for anti-cancer drug achieves primary objectives (www.pipelinereview.com)
Cytopias new agent CY997 has met it's phase I goal to determine MTD and DLT - not a hard task to have done.   Either it's tolerable and safe or not tolerable and not safe.   In this case, the former holds true. However, without more significant clinical data - phase II and III -...
Analysis of: By 2008, Medicare won't pay for hospital errors (www.fiercehealthcare.com)
Well....we know CMS doesn't have enough money to fund healthcare in perpetuity.   Physicians have been taking reimbursement cuts or lack of raises over the last 5 years.    Realizing you can't squezze enough money out of the physicians, Medican now brilliantly plans to...
Analysis of: Oncoscience AG, the european partner of YM BioSciences, announces completion of patient enrollment in phase III brain cancer trial of nimotuzab (www.pipelinereview.com)
Glioblastomas and diffuse pontine gliomas in adults and children are agressive, and nearly universally fatal.  The standard of care today for GBMs is concurrent chemoradiotherapy with Temodar, based on the results of the NCIC trial (Stupp, et al., NEJM, 352:987-96, 2005).   For diffuse...
Glen McDaniel, MS, MBA, President and Chief Executive Officer
Glen McDaniel, MS, MBA, President and Chief Executive Officer
GM Global
Analysis of: By 2008, Medicare won't pay for hospital errors (www.fiercehealthcare.com)
- Some studies show that medical errors continue to increase despite an intense focus on this issue over the last recent years. This decision by CMS should bring even more attention to this whole area of patient safety and error prevention - There will need to be increased documentation to "prove"...
Analysis of: Spectrum Pharmaceuticals Investigational New Drug Application for SPI-1620 Cleared by U.S. Food & Drug Administration (www.pipelinereview.com)
There are many theories out there about how angiogenesis affects tumor growth.   One theory is that anti-angiogenic agents emilinate the leakiness of blood vessels, improving flow of blood and chemotherapy to the tumor, essentially getting more of a cytotoxic agent to the target. SPI-1620...
Analysis of: Hand Hygiene Promotion Decreases Healthcare-Associated Infections in Very-Low-Birth-Weight Neonates (www.medscape.com)
It's not a surprise that washing your hands frequently reduces the spread of infections.    This study verifies what we already know - frequent hand washing between each patient encounter reduces the spread of infections in very low birthweight babies. With aggressive intervention, we...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next51 to 60 of 155

Analytics


Generated at 2009-01-07T19:00:58.307